A novel strategy to increase the healing rate of leg ulcers
| Reference number | |
| Coordinator | Instagraft AB |
| Funding from Vinnova | SEK 999 900 |
| Project duration | June 2017 - December 2020 |
| Status | Completed |
Purpose and goal
The aim was to evaluate the synergy effect of two innovative treatments for leg ulcers. These include Lundatex® compression products, a patented technology for achieving well-defined pressure, and Instagraft®, a new tool for minimally invasive skin transplantation.
Expected results and effects
The number of visits to the clinic decreased by more than 50%. The synergy effect through the combination of the new microtransplantation technique and the controlled compression showed such promising results that it has the potential to shorten the wound healing time and at the same time improve the cost-effectiveness.
Planned approach and implementation
The project was divided into WP1 (Ethics, regulatory approval and set-up of the clinical trial), WP2 (Improvement of the existing prototypes), WP3 (Clinical trial), WP4 (Evaluation of the results and communication to the final users) and WP5 (Payment models and business strategy). The arrangement worked well despite delays due to adjustments to the ethics application and difficulties with patient recruitment. During spring 2020, the project was paused due to Covid-19 and but could be restarted and terminated during autumn 2020. More patients will be recruited in an expanded study.